U.S. Specialty drugmaker Allergan has announced that it will buy MAP Pharmaceuticals, a purchase that will intensify Allergan’s presence in medicines for the treatment of adult migraines. Allergan manufactures Botox, which in the last few years has received regulatory approvals in 56 countries for it’s use in treating chronic migraine. Map Pharmaceuticals has been developing Levadex, an orally inhaled drug for the acute treatment of migraines in adults. The drug is under review by the FDA, with a decision expected to be announced sometime in April. “We plan to capitalize on depth of expertise in neurology as we continue the global development of Levadex as a potential acute treatment for migraine,” said Allergan Chief Executive David Pyott. Allergan will pay close to one billion dollars for the purchase of Map Pharmaceuticals……….  Yahoo! News  1/23/13

Subscribe To Our Weekly Newsletter

Subscribe To Our Weekly Newsletter

Get a weekly digest of our posts straight to your inbox! We promise, no spam ever.

You have Successfully Subscribed!

Pin It on Pinterest

Share This